Phenotypic, biochemical, and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity

Antimicrobial Agents and Chemotherapy

Volumn 63, Issue 12, 2019, Pages

  Mueller, Linda ^a,b,c   Masseron, Amandine ^a   Prod’Hom, Guy ^c   Galperine, Tatiana ^c   Greub, Gilbert ^c   Poirel, Laurent ^a,b   Nordmann, Patrice ^a,b,c  

^a University of Fribourg   (Switzerland)

^b UNIVERSITY OF FRIBOURG   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Ceftazidime avibactam; Klebsiella pneumoniae; KPC

Indexed keywords

AMINO ACID; AMOXICILLIN; AVIBACTAM; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; BETA LACTAMASE; BETA LACTAMASE KPC 3; BETA LACTAMASE KPC 41; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEFALOTIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAROLINE; CEFTAZIDIME; CEFTOLOZANE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIN; ERTAPENEM; IMIPENEM; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; TAZOBACTAM; TICARCILLIN; UNCLASSIFIED DRUG;

AGED; AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC RESISTOME; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BINDING AFFINITY; BIOCHEMICAL ANALYSIS; CASE REPORT; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; ESCHERICHIA COLI; GENETIC ANALYSIS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; KINETIC PARAMETERS; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LOADING DRUG DOSE; MALE; MEDICAL HISTORY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; NULL RESULT; PANCREAS CANCER; PANCREAS SURGERY; PERITONITIS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WHOLE GENOME SEQUENCING;

EID: 85075562906     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01111-19     Document Type: Article

References (23)

1. Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemases producers in Enterobacteriaceae. Emerg Infect Dis 17:1791–1798. https://doi.org/10.3201/eid1710.110655.
2. Van Duin D, Bonomo RA. 2016. Ceftazidime/avibactam and ceftolozane/ tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis 63:234–241. https://doi.org/10.1093/cid/ciw243.
3. Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, Gregson A. 2015. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother 59:6605– 6607. https://doi.org/10.1128/AAC.01165-15.
4. Shields RK, Chen L, Cheng S, Chavda KD, Press EG. 2017. Emergence of ceftazidime-avibactam mutations during treatment. Antimicrob Agents Chemother 61:e02097-16. https://doi.org/10.1128/AAC.02097-16.
5. Hemarajata P, Humphries RM. 7 February 2019. Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2. J Antimicrob Chemother https://doi.org/10.1093/jac/dkz026.
6. Gregory CJ, Llata E, Stine N, Gould C, Santiago LM, Vazquez GJ, Robledo IE, Srinivasan A, Goering RV, Tomashek KM. 2010. Outbreak of carbapenemresistant Klebsiella pneumoniae in Puerto Rico associated with a novel carbapenemase variant. Infect Control Hosp Epidemiol 31:476–484. https://doi.org/10.1086/651670.
7. Barnes MD, Winkler ML, Taracila MA, Page MG, Desarbre E, Kreiswirth BN, Shields RK, Nguyen M-H, Clancy C, Spellberg B, Papp-Wallace KM, Bonomo RA. 2017. Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at Ambler position Asp179, and resistance to ceftazidime-avibactam: unique antibiotic-resistant phenotypes emerge from β-lactamase protein engineering. mBio 8:e00528-17. https://doi.org/10.1128/mBio.00528-17.
8. Livermore DM, Warner M, Jamrozy D, Mushtaq S, Nichols WW, Mustafa N, Woodford N. 2015. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 59:5324–5330. https://doi.org/10.1128/AAC.00678-15.
9. Winkler ML, Papp-Wallace KM, Bonomo RA. 2015. Activity of ceftazidime/ avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the loop. J Antimicrob Chemother 70:2279–2286. https://doi.org/10.1093/jac/dkv094.
10. Compain F, Arthur M. 2017. Impaired inhibition by avibactam and resistance to the ceftazidime-avibactam combination due to the D179Y substitution in the KPC-2 β-lactamase. Antimicrob Agents Chemother 61:e00451-17. https://doi.org/10.1128/AAC.00451-17.
11. Galani I, Antoniadou A, Karaiskos I, Kontopoulou K, Giamarellou H, Souli M. 2019. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam. Clin Microbiol Infect 25:763.e5–763.e8. https://doi.org/10.1016/j.cmi.2019.03.011.
12. Maida CM, Bonura C, Geraci DM, Graziano G, Carattoli A, Rizzo A, Torregrossa MV, Vecchio D, Giuffrè M. 2018. Outbreak of ST395 KPC-producing Klebsiella pneumoniae in a neonatal intensive care unit in Palermo. Infect Control Hosp Epidemiol 39:496–498. https://doi.org/10.1017/ice.2017.267.
13. Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. 2017. Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: a case report and review of literature. Open Forum Infect Dis 4:ofx101. https://doi.org/10.1093/ofid/ofx101.
14. Alba J, Ishii Y, Thomson K, Moland ES, Yamaguchi K. 2005. Kinetics study of KPC-3, a plasmid-encoded class A carbapenem-hydrolyzing βlactamase. Antimicrob Agents Chemother 49:4760–4762. https://doi.org/10.1128/AAC.49.11.4760-4762.2005.
15. Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. 2017. In vitro selection of meropenem resistance among ceftazidime-avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases. Antimicrob Agents Chemother 61:e00079-17. https://doi.org/10.1128/AAC.00079-17.
16. Bulik CC, Nicolau DP. 2011. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 55: 3002–3004. https://doi.org/10.1128/AAC.01420-10.
17. Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. 2005. Identification of plasmids by PCR-based replicon typing. J Microbiol Methods 63:219–228. https://doi.org/10.1016/j.mimet.2005.03.018.
18. Nordmann P, Poirel L, Dortet L. 2012. Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 18:1503–1507. https://doi.org/10.3201/eid1809.120355.
19. EUCAST. 2019. Breakpoint tables for interpretation of MICs and zone diameters. Version 9. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_9_Breakpoint_Tables.pdf.
20. Nordmann P, Jayol A, Poirel L. 2016. Rapid detection of polymyxin resistance in Enterobacteriaceae. Emerg Infect Dis 22:1038–1043. https://doi.org/10.3201/eid2206.151840.
21. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, Bairoch A. 2005. Protein identification and analysis tools on the ExPASy server. In Walker JM (ed), The proteomics protocols handbook. Humana Press, Totowa, NJ.
22. Gaibani P, Campoli C, Lewis RE, Volpe SL, Scaltriti E, Giannella M, Pongolini S, Berlingeri A, Cristini F, Bartoletti M, Tedeschi S, Ambretti S. 2018. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother 73:1525–1529. https://doi.org/10.1093/jac/dky082.
23. Kieffer N, Nordmann P, Aires-de-Sousa M, Poirel L. 2016. High prevalence of carbapenemase-producing Enterobacteriaceae among hospitalized children in Luanda, Angola. Antimicrob Agents Chemother 60: 6189–6192. https://doi.org/10.1128/AAC.01201-16.